All Articles

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

As global supply chains shift, a conference in Montreal highlights a crucial trade realignment. But are Canadian firms ready to seize the massive EU opportunity?

With a key investor presentation looming, USA Rare Earth is executing an ambitious mine-to-magnet strategy to end reliance on foreign rare earth metals.

For many rural families, a child's heart defect was a death sentence. Now, a coal company's ambitious CSR program is rewriting their future, one tiny heart at a time.

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.

Gary Clark dissects Avance Clinical's bold move into Asia's booming biotech hubs, revealing why the region is now essential for global drug development.

A junior miner's modest financing gets a big boost from a veteran resource investor, shining a spotlight on New Brunswick's critical mineral ambitions.

A small travel platform bets big on North America-India routes, promising deep discounts and a better experience. But can it deliver against industry giants?

Belgravia Hartford's Gravitio AI boasts impressive prediction stats, but unverified metrics and a precarious financial backdrop reveal a high-stakes gamble.

While Beijing touts economic partnership, its deepening ties with Myanmar's isolated junta raise critical questions about debt, dependency, and regional stability.

While crypto exchanges tout record trading on SpaceX derivatives, a behind-the-scenes failure to secure actual shares reveals a deep rift with traditional finance.

MEXC's new Ondo tokenized stocks offer global access to US equities, but a deep dive reveals significant platform-level risks that clash with the product's promise.

Aether Education's expansion reveals a deeper trend in Hong Kong: a high-stakes, privatized system where 'character' is the new competitive credential.

MEXC reports $800M in daily volume for its SpaceX derivatives, but as crypto platforms replicate Wall Street products, are they democratizing finance or just risk?

As AI-driven attacks loom over critical infrastructure, IBM is arming its legacy Z mainframes with a new suite of AI-powered defensive tools.

As Québec's population ages, a major healthcare union launches a campaign to confront systemic failures in senior care, challenging government strategy.

Beyond the handshakes and high-speed train rides, the new China-Myanmar pact reveals a strategic calculus that could reshape Asia's geopolitical landscape.

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

ISS is set to unveil its next strategic chapter. With a focus on North American expansion and operational excellence, what should investors watch for?

With a new strategic funding round, LUMIQ aims to scale its autonomous AI, which makes auditable decisions in minutes, not weeks, for banks and insurers.